Comment
doi: 10.1016/S1470-2045(12)70457-6.
Epub 2012 Oct 17.
MDM2 inhibition in liposarcoma: a step in the right direction
- PMID: 23084518
- DOI: 10.1016/S1470-2045(12)70457-6
Item in Clipboard
Comment
MDM2 inhibition in liposarcoma: a step in the right direction
Lancet Oncol.
2012 Nov.
No abstract available
Comment on
-
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.Lancet Oncol. 2012 Nov;13(11):1133-40. doi: 10.1016/S1470-2045(12)70474-6. Epub 2012 Oct 17. Lancet Oncol. 2012. PMID: 23084521
Similar articles
-
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.Lancet Oncol. 2012 Nov;13(11):1133-40. doi: 10.1016/S1470-2045(12)70474-6. Epub 2012 Oct 17. Lancet Oncol. 2012. PMID: 23084521
-
HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status.Oncotarget. 2015 Apr 30;6(12):10510-20. doi: 10.18632/oncotarget.3230. Oncotarget. 2015. PMID: 25888633 Free PMC article.
-
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.Int J Cancer. 2007 Jul 1;121(1):199-205. doi: 10.1002/ijc.22643. Int J Cancer. 2007. PMID: 17354236
-
Discovery of Potent and Selective p53-MDM2 Protein-Protein Interaction Inhibitors as Anticancer Drugs.Chimia (Aarau). 2017 Oct 25;71(10):716-721. doi: 10.2533/chimia.2017.716. Chimia (Aarau). 2017. PMID: 29070416 Review.
-
Resistance acquisition to MDM2 inhibitors.Biochem Soc Trans. 2014 Aug;42(4):752-7. doi: 10.1042/BST20140035. Biochem Soc Trans. 2014. PMID: 25109953 Review.
Cited by
-
A Rare Case of Dedifferentiated Retroperitoneal Liposarcoma Presenting As Cardiac-Sounding Chest Pain.Cureus. 2021 Nov 12;13(11):e19503. doi: 10.7759/cureus.19503. eCollection 2021 Nov. Cureus. 2021. PMID: 34790501 Free PMC article.
-
Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.PLoS One. 2015 Aug 6;10(8):e0135101. doi: 10.1371/journal.pone.0135101. eCollection 2015. PLoS One. 2015. PMID: 26248031 Free PMC article.
-
Epigenetic therapy for ovarian cancer: promise and progress.Clin Epigenetics. 2019 Jan 15;11(1):7. doi: 10.1186/s13148-018-0602-0. Clin Epigenetics. 2019. PMID: 30646939 Free PMC article. Review.
-
SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.Clin Cancer Res. 2016 Mar 1;22(5):1150-60. doi: 10.1158/1078-0432.CCR-15-1522. Epub 2015 Oct 16. Clin Cancer Res. 2016. PMID: 26475335 Free PMC article.
-
Retroperitoneal liposarcoma: current insights in diagnosis and treatment.Front Surg. 2015 Feb 10;2:4. doi: 10.3389/fsurg.2015.00004. eCollection 2015. Front Surg. 2015. PMID: 25713799 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
